Latest news with #XVIVO
Yahoo
a day ago
- Business
- Yahoo
XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market
GOTHENBURG, SWEDEN / / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA) Business Award 2025, presented at the Swedish Embassy - House of Sweden - in Washington, D.C. The SACC-USA Business Award honors companies that strengthen Swedish-American business ties through industry excellence, innovation, and cross-border impact. "To win the SACC-USA Business Award is a tremendous honor and a testament to our team's unwavering commitment to saving lives," said Christoffer Rosenblad, CEO of XVIVO. "It affirms the importance of our vision that nobody should die waiting for a new organ and reinforces our momentum as we continue to help clinicians and researchers push the boundaries of organ transplantation to serve more patients in the U.S." The award highlights the deep connection between Swedish innovation and advancements in American healthcare. Following a year of substantial growth in the U.S. market, XVIVO's success is driven by the increasing need for organ perfusion and preservation technologies that help transplant teams save more lives. "As the demand for more organs continues to grow, XVIVO is supporting the system through groundbreaking solutions rooted in science, technology, and measurable impact," said André Persson, Jury Chair, SACC USA Business Award, with SACC-USA. "Their rapid growth and transformative contributions to the U.S. healthcare system exemplify the forward-thinking innovation we celebrate with the SACC-USA Business Award." June 13, 2025GothenburgChristoffer Rosenblad, CEOXVIVO Perfusion AB (publ) For further information, please contact: Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: Nordström, CFO, +46 73 519 21 64, e-mail: About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website Attachments XVIVO honored with 2025 SACC-USA Business Award for life-saving innovation and growth in the U.S. market SOURCE: XVIVO Perfusion AB View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market
GOTHENBURG, SWEDEN / / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA) Business Award 2025, presented at the Swedish Embassy - House of Sweden - in Washington, D.C. The SACC-USA Business Award honors companies that strengthen Swedish-American business ties through industry excellence, innovation, and cross-border impact. "To win the SACC-USA Business Award is a tremendous honor and a testament to our team's unwavering commitment to saving lives," said Christoffer Rosenblad, CEO of XVIVO. "It affirms the importance of our vision that nobody should die waiting for a new organ and reinforces our momentum as we continue to help clinicians and researchers push the boundaries of organ transplantation to serve more patients in the U.S." The award highlights the deep connection between Swedish innovation and advancements in American healthcare. Following a year of substantial growth in the U.S. market, XVIVO's success is driven by the increasing need for organ perfusion and preservation technologies that help transplant teams save more lives. "As the demand for more organs continues to grow, XVIVO is supporting the system through groundbreaking solutions rooted in science, technology, and measurable impact," said André Persson, Jury Chair, SACC USA Business Award, with SACC-USA. "Their rapid growth and transformative contributions to the U.S. healthcare system exemplify the forward-thinking innovation we celebrate with the SACC-USA Business Award." June 13, 2025GothenburgChristoffer Rosenblad, CEOXVIVO Perfusion AB (publ) For further information, please contact: Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: Nordström, CFO, +46 73 519 21 64, e-mail: About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website Attachments XVIVO honored with 2025 SACC-USA Business Award for life-saving innovation and growth in the U.S. market SOURCE: XVIVO Perfusion AB View the original press release on ACCESS Newswire
Yahoo
10-05-2025
- Business
- Yahoo
TransMedics Group, Inc. (TMDX): A Bull Case Theory
We came across a bullish thesis on TransMedics Group, Inc. (TMDX) on Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls' thesis on TMDX. TransMedics Group, Inc. (TMDX)'s share was trading at $95.81 as of May 7th. TMDX's trailing and forward P/E were 89.54 and 63.29 respectively according to Yahoo Finance. A doctor performing a living donor kidney transplant in a hospital operating room, emphasizing the importance of medical advancements. TransMedics (TMDX), founded by cardiothoracic surgeon Dr. Waleed Hassanein, is revolutionizing the field of organ transplantation with its proprietary warm perfusion technology. Dr. Hassanein identified a critical flaw in the traditional approach of cold organ storage, which keeps organs in a dormant state and significantly limits their viability, repair potential, and transplant suitability. In contrast, TransMedics' Organ Care System enables organs to remain alive and functioning outside the human body, supplied with oxygen and nutrients in a warm environment. This breakthrough allows for better organ assessment, extended preservation time, and even organ improvement prior to transplant. Competing firms like Sweden's XVIVO Perfusion and the UK's OrganOx are the only other significant players in the warm storage space, but the overall competitive landscape remains sparse due to the immense technological, logistical, and regulatory hurdles involved. These barriers have helped TransMedics build a robust competitive moat. The company's impact is especially vital considering the underwhelming organ utilization rates in the U.S.: kidneys are discarded 28% of the time, and over 70% of hearts and lungs go unused. Cold storage's inability to preserve donation after circulatory death and donation after brain death organs compounds this problem. TMDX's OCS technology directly addresses this issue, enhancing transplant viability for these previously challenging donor types. The company has further integrated this technology with its National OCS Program, an end-to-end service for organ transplant logistics and execution. In 2023, TMDX executed 3,715 OCS cases, with long-term goals of 10,000 annually and eventual targets of 20,000–30,000 as it expands into international markets and kidney transplants. Notably, OCS product sales now represent about 61% of company revenue, with the remainder coming from services tied to transplantation logistics. TMDX has experienced explosive growth, with revenues growing at 90–200% annually in recent years. Despite this, the stock has pulled back significantly from its all-time highs around $180, now trading near $95—a 47% decline. This reset in valuation has created a highly attractive entry point for investors, especially with the company already achieving profitability in Q4 2023 and gross margins around 60%. However, net margins have yet to scale materially due to early-stage investments, including the expansion of their aviation fleet, which plays a central role in logistics and introduces short-term variability in margins. TMDX's Q1 2025 earnings are highly anticipated (scheduled for May 8), and bullish indicators abound. Public flight data—correlated with organ transport cases—suggests the company conducted 2,115 flights in the quarter. Using a conservative $66,000 per-flight revenue estimate implies $139.6 million in revenue, which far exceeds the company's Q1 guidance of $123.4 million. Even accounting for unknowns like organ mix, internal versus external flight use, and differing revenue per case, estimates of $140–144 million seem plausible. Such results could lead management to raise full-year guidance beyond the already strong $530–552 million (20–25% YoY growth), a move that could trigger a sharp revaluation in the stock. If revenue comes in at the upper end or exceeds $142 million, a 10%+ move post-earnings is possible, further supported by the company's solid margin outlook and de-risked guidance. Beyond the near-term numbers, TMDX's long-term thesis remains intact. Its addressable market may be finite in terms of total organ transplants, but its role in expanding transplant viability increases the effective TAM. Moreover, TMDX's end-to-end solution, from organ perfusion to logistics, positions it as a critical partner in the healthcare system—not just a device manufacturer. While some investors have raised concerns about aviation fleet costs or were spooked by a short report earlier in 2025, these issues appear transient and are dwarfed by the company's execution strength and transformative potential. At current levels, the estimated fair value price by 2030 is $368.2, suggesting substantial upside potential as execution continues. With high barriers to entry, limited competition, regulatory know-how, and proven growth, TMDX represents a compelling long-term investment opportunity in one of the most mission-critical and underserved areas of modern medicine. TransMedics Group, Inc. (TMDX) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held TMDX at the end of the fourth quarter which was 32 in the previous quarter. While we acknowledge the risk and potential of TMDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TMDX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Interim Report January-March 2025
GOTHENBURG, SE / / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) First quarter 2025 (Jan-Mar) Net sales increased to SEK 218.6 million (186.0), corresponding to growth of 18 percent in SEK and 16 percent in local currencies. Organic growth amounted to 14 percent in local currencies. The Business areas Thoracic and Abdominal delivered sales growth in local currencies: Thoracic 16 percent and Abdominal 28 percent. Services delivered negative growth of -6 percent. Total gross margin was 73 percent (73). The gross margin for the business areas amounted to: Thoracic 82 percent (81), Abdominal 63 percent (68) and Services 38 percent (36). Operating income (EBIT) increased to SEK 26.6 million (19.0). Adjusted EBIT increased by 50 percent to SEK 29.8 million (19.9). Operating income before depreciation and amortization (EBITDA) increased to SEK 43.0 million (36.0), corresponding to an EBITDA margin of 20 percent (19). Adjusted EBITDA increased to SEK 46.2 million (36.9), corresponding to an adjusted EBITDA margin of 21 percent (20). Net profit amounted to SEK -12.4 million (22.8), impacted by currency effects in cash and cash equivalents of SEK -22.5 million (8.3). Earnings per share amounted to SEK -0.39 (0.72). Cash flow from operating activities was SEK -15.3 million (1.6). The quarter was impacted by increased working capital tied up due to higher sales, as well as the annual payout of employee-related liabilities. Total cash flow amounted to SEK -77.2 million (-43.3), primarily impacted by investments in R&D projects of SEK -40.1 million. Significant events in the quarter Rapid FDA approval of the IDE application for the DELIVER study using Liver Assist FDA approval for continued use of XVIVO's heart technology through the PRESERVE CAP study For further information, please contact: Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: Conference Call Christoffer Rosenblad, CEO and Kristoffer Nordström, CFO, will present the report in a conference call today at 2.00 PM CET / 8.00 AM EST. For registration to the conference call, see information in previous press release: About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-24 07:30 CEST. Attachments XVIVO Interim Report Q1 2025 SOURCE: XVIVO Perfusion AB View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
15-04-2025
- Business
- Yahoo
Conference Call on Interim Report January-March 2025
GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025. The presentation will be held in English. Time: Thursday, April 24 at 2.00 pm CET / 8.00 am EST If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions. If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions Participants from XVIVO:Christoffer Rosenblad, CEOKristoffer Nordström, CFO A press release containing XVIVO's interim report January-March 2025 will be released on April 24, 2025 at 7.30 am CET / 1.30 am EST. Before the conference call, slides will be available at the company web page, April 15, 2025MölndalXVIVO Perfusion AB (publ) For further information, please contact: Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: Nordström, CFO, +46 73 519 21 64, e-mail: About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website Attachments Conference call on Interim Report January-March 2025 SOURCE: XVIVO Perfusion AB View the original press release on ACCESS Newswire
